Does the media favor GKOS or GEHC?

In the previous week, GE HealthCare Technologies had 18 more articles in the media than Glaukos. MarketBeat recorded 32 mentions for GE HealthCare Technologies and 14 mentions for Glaukos. Glaukos' average media sentiment score of 0.61 beat GE HealthCare Technologies' score of 0.60 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GE HealthCare Technologies 13 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts recommend PHG or GKOS?

Glaukos has a consensus price target of $155.23, suggesting a potential upside of 2.35%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Glaukos 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73

Which has stronger valuation and earnings, PHG or GKOS?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.25 $1.01B $1.17 21.84 Glaukos $551.35M 16.16 -$187.69M -$3.28 N/A

Does the media refer more to PHG or GKOS?

In the previous week, Koninklijke Philips had 2 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for Koninklijke Philips and 14 mentions for Glaukos. Glaukos' average media sentiment score of 0.61 beat Koninklijke Philips' score of 0.61 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Glaukos 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $551.35M 16.16 -$187.69M -$3.28 N/A Zimmer Biomet $8.23B 2.25 $705.20M $3.85 24.82

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Zimmer Biomet 9.05% 13.24% 7.28%

Does the media favor GKOS or ZBH?

In the previous week, Zimmer Biomet had 5 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for Zimmer Biomet and 14 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.19 beat Glaukos' score of 0.61 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 13 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GKOS or SOLV?

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $551.35M 16.16 -$187.69M -$3.28 N/A Solventum $8.33B 1.79 $1.56B $8.16 10.57

Is GKOS or SOLV more profitable?

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Solventum 17.33% 23.51% 7.63%

Does the media prefer GKOS or SOLV?

In the previous week, Glaukos had 3 more articles in the media than Solventum. MarketBeat recorded 14 mentions for Glaukos and 11 mentions for Solventum. Solventum's average media sentiment score of 0.97 beat Glaukos' score of 0.61 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, GKOS or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Glaukos. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $551.35M 16.16 -$187.69M -$3.28 N/A Smith & Nephew SNATS $6.16B 2.23 $625M N/A N/A

Does the media prefer GKOS or SNN?

In the previous week, Glaukos had 13 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for Glaukos and 1 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.61 beat Smith & Nephew SNATS's score of 0.33 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Live Earnings Conference Call: Glaukos will host a live Q2 2026 earnings call on July 29, 2026 at 4:30PM ET. Get details.

Glaukos (GKOS) Competitors

$151.66 -0.25 (-0.16%)

Closing price 07/28/2026 03:59 PM Eastern

Extended Trading

$151.56 -0.10 (-0.07%)

As of 04:08 AM Eastern

Compare

GKOS vs. GEHC, PHG, ZBH, SOLV, and SNN

Should you buy Glaukos stock or one of its competitors? MarketBeat compares Glaukos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Glaukos include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Glaukos compare to GE HealthCare Technologies?

Glaukos (NYSE:GKOS) and GE HealthCare Technologies (NASDAQ:GEHC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

GE HealthCare Technologies has a net margin of 9.10% compared to Glaukos' net margin of -34.34%. GE HealthCare Technologies' return on equity of 20.46% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
GE HealthCare Technologies	9.10%	20.46%	5.73%

Glaukos presently has a consensus target price of $155.23, suggesting a potential upside of 2.35%. GE HealthCare Technologies has a consensus target price of $76.41, suggesting a potential upside of 19.18%. Given GE HealthCare Technologies' higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
GE HealthCare Technologies	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$551.35M	16.16	-$187.69M	-$3.28	N/A
GE HealthCare Technologies	$20.63B	1.41	$2.08B	$4.18	15.34

In the previous week, GE HealthCare Technologies had 18 more articles in the media than Glaukos. MarketBeat recorded 32 mentions for GE HealthCare Technologies and 14 mentions for Glaukos. Glaukos' average media sentiment score of 0.61 beat GE HealthCare Technologies' score of 0.60 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	13 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Glaukos has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

GE HealthCare Technologies beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Koninklijke Philips had 2 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for Koninklijke Philips and 14 mentions for Glaukos. Glaukos' average media sentiment score of 0.61 beat Koninklijke Philips' score of 0.61 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Glaukos	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has a consensus price target of $155.23, suggesting a potential upside of 2.35%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

13.7% of Koninklijke Philips shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Koninklijke Philips has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Koninklijke Philips has a net margin of 5.49% compared to Glaukos' net margin of -34.34%. Koninklijke Philips' return on equity of 13.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Glaukos	-34.34%	-6.92%	-5.25%

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.25	$1.01B	$1.17	21.84
Glaukos	$551.35M	16.16	-$187.69M	-$3.28	N/A

Summary

Koninklijke Philips beats Glaukos on 8 of the 15 factors compared between the two stocks.

How does Glaukos compare to Zimmer Biomet?

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Zimmer Biomet had 5 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for Zimmer Biomet and 14 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.19 beat Glaukos' score of 0.61 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	13 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$551.35M	16.16	-$187.69M	-$3.28	N/A
Zimmer Biomet	$8.23B	2.25	$705.20M	$3.85	24.82

Glaukos has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Zimmer Biomet	9.05%	13.24%	7.28%

Glaukos presently has a consensus price target of $155.23, suggesting a potential upside of 2.35%. Zimmer Biomet has a consensus price target of $102.00, suggesting a potential upside of 6.72%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.29

Summary

Zimmer Biomet beats Glaukos on 11 of the 17 factors compared between the two stocks.

How does Glaukos compare to Solventum?

Glaukos (NYSE:GKOS) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$551.35M	16.16	-$187.69M	-$3.28	N/A
Solventum	$8.33B	1.79	$1.56B	$8.16	10.57

Glaukos has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Glaukos presently has a consensus target price of $155.23, indicating a potential upside of 2.35%. Solventum has a consensus target price of $86.00, indicating a potential downside of 0.30%. Given Glaukos' stronger consensus rating and higher possible upside, equities research analysts plainly believe Glaukos is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Solventum	17.33%	23.51%	7.63%

99.0% of Glaukos shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Glaukos had 3 more articles in the media than Solventum. MarketBeat recorded 14 mentions for Glaukos and 11 mentions for Solventum. Solventum's average media sentiment score of 0.97 beat Glaukos' score of 0.61 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Glaukos and Solventum tied by winning 8 of the 16 factors compared between the two stocks.

How does Glaukos compare to Smith & Nephew SNATS?

Glaukos (NYSE:GKOS) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Glaukos has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

In the previous week, Glaukos had 13 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for Glaukos and 1 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.61 beat Smith & Nephew SNATS's score of 0.33 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Glaukos currently has a consensus price target of $155.23, indicating a potential upside of 2.35%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential downside of 4.95%. Given Glaukos' stronger consensus rating and higher possible upside, research analysts clearly believe Glaukos is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Smith & Nephew SNATS has higher revenue and earnings than Glaukos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$551.35M	16.16	-$187.69M	-$3.28	N/A
Smith & Nephew SNATS	$6.16B	2.23	$625M	N/A	N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. Smith & Nephew SNATS's return on equity of 0.00% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Smith & Nephew SNATS	N/A	N/A	N/A

Summary

Glaukos beats Smith & Nephew SNATS on 9 of the 14 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$8.92B	$7.54B	$7.08B	$23.66B
Dividend Yield	N/A	1.30%	2.66%	4.21%
P/E Ratio	-46.24	48.08	27.24	31.08
Price / Sales	16.16	96.94	520.20	14.27
Price / Cash	N/A	25.93	49.60	31.92
Price / Book	13.28	7.05	10.24	4.83
Net Income	-$187.69M	$162.27M	$3.60B	$1.07B
7 Day Performance	-0.75%	0.45%	-0.96%	0.69%
1 Month Performance	6.71%	-3.56%	-3.60%	0.89%
1 Year Performance	61.50%	4.39%	20.54%	15.67%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	1.7602 of 5 stars	$151.66 -0.2%	$155.23 +2.4%	+60.0%	$8.92B	$551.35M	N/A	1,094	Analyst Forecast Insider Trade
GEHC GE HealthCare Technologies	4.7086 of 5 stars	$62.83 -0.4%	$76.41 +21.6%	-17.5%	$28.69B	$20.63B	15.03	54,000
PHG Koninklijke Philips	2.5441 of 5 stars	$26.77 -0.7%	N/A	-0.4%	$26.49B	$20.17B	22.94	65,340	Trending News Gap Down
ZBH Zimmer Biomet	3.0058 of 5 stars	$89.69 -1.6%	$100.70 +12.3%	-0.4%	$17.63B	$8.41B	23.30	17,000	Positive News Upcoming Earnings Analyst Forecast
SOLV Solventum	3.005 of 5 stars	$79.22 -2.6%	$81.91 +3.4%	+16.9%	$14.08B	$8.33B	9.71	20,000	News Coverage Upcoming Earnings Analyst Upgrade Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors

GKOS vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Glaukos compare to GE HealthCare Technologies?

Summary

How does Glaukos compare to Koninklijke Philips?

Summary

How does Glaukos compare to Zimmer Biomet?

Summary

How does Glaukos compare to Solventum?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glaukos (GKOS) Competitors

GKOS vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Glaukos compare to GE HealthCare Technologies?

Is GKOS or GEHC more profitable?

Do analysts rate GKOS or GEHC?

Which has higher valuation and earnings, GKOS or GEHC?

Does the media favor GKOS or GEHC?

Which has more risk and volatility, GKOS or GEHC?

Do insiders & institutionals have more ownership in GKOS or GEHC?

Summary

How does Glaukos compare to Koninklijke Philips?

Does the media refer more to PHG or GKOS?

Do analysts recommend PHG or GKOS?

Do institutionals and insiders have more ownership in PHG or GKOS?

Which has more risk and volatility, PHG or GKOS?

Is PHG or GKOS more profitable?

Which has stronger valuation and earnings, PHG or GKOS?

Summary

How does Glaukos compare to Zimmer Biomet?

Does the media favor GKOS or ZBH?

Which has stronger earnings and valuation, GKOS or ZBH?

Which has more volatility & risk, GKOS or ZBH?

Do institutionals & insiders have more ownership in GKOS or ZBH?

Is GKOS or ZBH more profitable?

Do analysts rate GKOS or ZBH?

Summary

How does Glaukos compare to Solventum?

Which has preferable earnings and valuation, GKOS or SOLV?

Which has more volatility and risk, GKOS or SOLV?

Do analysts rate GKOS or SOLV?

Is GKOS or SOLV more profitable?

Do institutionals and insiders believe in GKOS or SOLV?

Does the media prefer GKOS or SOLV?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Which has more risk & volatility, GKOS or SNN?

Does the media prefer GKOS or SNN?

Do institutionals & insiders believe in GKOS or SNN?

Do analysts rate GKOS or SNN?

Which has stronger valuation and earnings, GKOS or SNN?

Is GKOS or SNN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools